The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Éric Rondeau(Sorbonne Université), Marie Scully(National Institute for Health and Care Research), Gema Ariceta(Vall d'Hebron Hospital Universitari), Tom Barbour(The Royal Melbourne Hospital), Spero Cataland(The Ohio State University Wexner Medical Center), Nils Heyne(University Children's Hospital Tübingen), Yoshitaka Miyakawa(Saitama Medical University), Stephan Ortiz(Alexion Pharmaceuticals (United States)), Eugene Swenson(Alexion Pharmaceuticals (United States)), Marc Vallée(Alexion Pharmaceuticals (United States)), Sung‐Soo Yoon(Seoul National University Hospital), David Kavanagh(University of Ulster), Hermann Haller(Medizinische Hochschule Hannover), Sunil Babu, Nilüfer Broeders, Nicole Lietar, Fiona G. Brown, Philip Campbell, Paramit Chowdhury, Theo Kasimatis, Lino Cirami, Leonardo Caroti, Guilia Antognoli, Yahsou Delmas, Vladimir Dobronravov, Anja Gaeckler, Cyril Garrouste, Gregory Greenwood, Siân Griffin, Chiu‐Ching Huang, I−Ru Chen, Susan S. Huang, Jin Seok Kim, Gaetano La Manna, Giorgia Comai, Maria Cappuccilli, Moglie Le Quintrec, Guillaume Jeantet, Iino Fumie, Yosu Luque, Jan Menne, J Morelle, Éric Goffin(Sorbonne Université), Anja Mühlfeld, Shashi Nagaraj, Gowthami M. Arepally, Doyeun Oh, Masayoshi Okumi, Manuel Praga Terente, Elena Gutiérrez, Paola Rodrı́guez, François Provôt, Ulf Schönermarck, Michael Fischereder, Natàlia Ramos Terrada, Barbara Seitz‐Polski, Guillaume Favrè, Sonia Boyer‐Suavet, Maria Vinogradova, Tatiana Kirsanova, Edwin Wong
Cited by 216Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis